trending Market Intelligence /marketintelligence/en/news-insights/trending/r3g61Ac3MEXM4Pxa8zRSWg2 content esgSubNav
In This List

Vifor partnering with ChemoCentryx on another kidney drug

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Vifor partnering with ChemoCentryx on another kidney drug

ChemoCentryx Inc. is expanding its alliance with Vifor Pharma to develop and commercialize another of its kidney drugs.

The companies will jointly develop CCX140 for more prevalent forms of chronic kidney disease with ChemoCentryx retaining rights in U.S. and China, and Vifor Pharma for the rest of the world.

ChemoCentryx will receive $50 million in upfront payment in exchange for the rights. It will also receive undisclosed payments once certain milestones are met, as well as royalty on future sales.

CCX140 previously cleared phase 2 clinical trial in patients with diabetic kidney disease.

Vifor Pharma first partnered with ChemoCentryx in May for rights to a possible treatment for rare and orphan kidney diseases, CCX168, in certain parts of the world.